INFU Share Price | InfuSystem Holdings, Inc. Stock Analysis & Recommendation

Q: How big is InfuSystem Holdings, Inc.?

Market Cap: As of Jun 18, InfuSystem Holdings, Inc. has a market capitalization of 150.88 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, InfuSystem reported net sales of 137.59 million and a net profit of 3.19 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 57.53 million and total assets of 110.88 million.

Q: What does InfuSystem Holdings, Inc. do?

Overview: InfuSystem Holdings, Inc. is a provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care, operating within the Miscellaneous industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 35 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025) Market-cap: USD 150.88 Million (Micro Cap)Key Metrics: P/E: 47.00 Dividend Yield: 0.00% Debt Equity: 0.49 Return on Equity: 5.78% Price to Book: 2.74Contact Details: Address: 31700 Research Park Dr, MADISON HEIGHTS MI: 48071-4627 Tel: ['1 248 2911210', '1 602 8899700'] Website: https://ir.infusystem.com/

Q: Is InfuSystem Holdings, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for InfuSystem Holdings, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish with a strong daily moving average indicating upward momentum. Weekly MACD and KST are also bullish, supporting the positive trend. However, the weekly and monthly RSI readings are bearish, suggesting some weakness in momentum. Despite this, the overall indicators lean towards a bullish outlook.In terms of performance, the stock has returned 18.82% year-to-date compared to the S&P 500's 12.22%, and it has significantly outperformed the benchmark over the past year with a return of 59.37% versus 17.14%.

Q: Is InfuSystem Holdings, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for InfuSystem Holdings, Inc. has moved from expensive to very expensive, indicating a significant concern regarding its valuation. The company appears to be overvalued based on its current metrics, with a P/E ratio of 47, a Price to Book Value of 2.71, and an EV to EBITDA of 8.31. When compared to peers, InfuSystem's P/E ratio is lower than Lincoln Educational Services Corp. at 59.63 but significantly higher than TaskUs, Inc. at 27.32, which is considered very attractive. The PEG ratio for InfuSystem is notably low at 0.01, suggesting that growth expectations may not justify its current price. While specific return data is not available, the absence of a positive return narrative against the S&P 500 reinforces the notion that the stock may not be a favorable investment at this time.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

61.68 k

Shareholding (Dec 2025)

FII

7.39%

Held by 42 FIIs

DII

70.37%

Held by 24 DIIs

Promoter

0.00%

How big is InfuSystem Holdings, Inc.?

22-Jun-2025

As of Jun 18, InfuSystem Holdings, Inc. has a market capitalization of 150.88 million, with net sales of 137.59 million and a net profit of 3.19 million over the latest four quarters.

View full answer

What does InfuSystem Holdings, Inc. do?

22-Jun-2025

InfuSystem Holdings, Inc. provides infusion pumps and related services for patients in various care settings, with a market cap of approximately $150.88 million. As of March 2025, it reported net sales of $35 million and no net profit.

View full answer

Who are in the management team of InfuSystem Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of InfuSystem Holdings, Inc. includes Mr. Scott Shuda (Independent Chairman), Mr. Richard Diiorio (President and CEO), Dr. Gregg Lehman (Vice Chairman), and three Independent Directors: Mr. Paul Gendron, Mr. Darrell Montgomery, and Mr. Christopher Sansone. They oversee the company's strategic direction and governance.

View full answer

Is InfuSystem Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, InfuSystem Holdings, Inc. has a bullish technical trend with strong daily moving averages and positive MACD and KST indicators, despite some bearish RSI readings, and has outperformed the S&P 500 year-to-date with an 18.82% return compared to 12.22%.

View full answer

Is InfuSystem Holdings, Inc. overvalued or undervalued?

05-Nov-2025

As of October 31, 2025, InfuSystem Holdings, Inc. is considered very expensive with a high P/E ratio of 47 and a low PEG ratio of 0.01, indicating it may be overvalued compared to peers and not a favorable investment.

View full answer

Compare InfuSystem Holdings, Inc. with Similar Stocks

Information Services Group, Inc.Augmedix, Inc.TaskUs, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Miscellaneous

Market cap

USD 227 Million (Micro Cap)

P/E

41.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.36

Return on Equity

9.96%

Price to Book

4.09

Revenue and Profits:

Net Sales:

36 Million

(Quarterly Results - Dec 2025)

Net Profit:

2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

7.46%

6 Months

-2.88%

1 Year

59.19%

2 Years

11.89%

3 Years

23.14%

4 Years

0.41%

5 Years

-51.29%

InfuSystem Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

8.37%

EBIT Growth (5y)

2.99%

EBIT to Interest (avg)

3.06

Debt to EBITDA (avg)

1.78

Net Debt to Equity (avg)

0.49

Sales to Capital Employed (avg)

1.58

Tax Ratio

51.74%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

84.74%

ROCE (avg)

6.38%

ROE (avg)

10.00%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.09

EV to EBIT

22.83

EV to EBITDA

10.22

EV to Capital Employed

3.28

EV to Sales

1.75

PEG Ratio

0.15

Dividend Yield

ROCE (Latest)

14.34%

ROE (Latest)

9.96%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 32 Schemes (22.24%)

Foreign Institutions

Held by 42 Foreign Institutions (7.39%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -0.82% vs 1.39% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -13.04% vs -11.54% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "36.20",
          "val2": "36.50",
          "chgp": "-0.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7.10",
          "val2": "7.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.50",
          "chgp": "-20.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.00",
          "val2": "2.30",
          "chgp": "-13.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "102.50%",
          "val2": "104.40%",
          "chgp": "-0.19%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 6.30% vs 7.23% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 186.96% vs 155.56% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "143.40",
          "val2": "134.90",
          "chgp": "6.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "25.20",
          "val2": "19.40",
          "chgp": "29.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.80",
          "val2": "2.50",
          "chgp": "-28.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6.60",
          "val2": "2.30",
          "chgp": "186.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "83.10%",
          "val2": "51.10%",
          "chgp": "3.20%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

36.20

36.50

-0.82%

Operating Profit (PBDIT) excl Other Income

7.10

Interest

0.40

0.50

-20.00%

Exceptional Items

0.00

Consolidate Net Profit

2.00

2.30

-13.04%

Operating Profit Margin (Excl OI)

102.50%

104.40%

-0.19%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is -0.82% vs 1.39% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -13.04% vs -11.54% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

143.40

134.90

6.30%

Operating Profit (PBDIT) excl Other Income

25.20

19.40

29.90%

Interest

1.80

2.50

-28.00%

Exceptional Items

0.00

Consolidate Net Profit

6.60

2.30

186.96%

Operating Profit Margin (Excl OI)

83.10%

51.10%

3.20%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 6.30% vs 7.23% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 186.96% vs 155.56% in Dec 2024

All Annual Results

Company CV

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc.

Miscellaneous

InfuSystem Holdings, Inc. is a provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers and other sites of care. The Company delivers local, field-based customer support and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Texas and Ontario, Canada. Its service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics for the treatment of a range of cancers, including colorectal cancer, pain management and other disease states. It sells or rents new and pre-owned pole mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for oncology practices, as well as other alternate site settings, including home care and home infusion providers, skilled nursing facilities, pain centers and others.

Company Coordinates

Company Details

31700 Research Park Dr , MADISON HEIGHTS MI : 48071-4627

Tel: 1 248 29112101 602 8899700

https://ir.infusystem.com/

Registrar Details